Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric pati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, Michael Loken, Lisa Brodersen, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2020-07-01
Colecção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/9939
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!